NEW DELHI – India's Central Drugs Standards Control Organisation (CDSCO) issued a slew of notifications in November aiming to speed up clinical trial approvals following concerns from companies that many regulatory requirements are duplicated and often tedious.
NEW DELHI – Controversy over drug price controls continues to pick up speed in India, as pharmaceutical and biotech companies find their bottom lines impacted by unpredictable pricing policies and risk.
NEW DELHI – Controversy over drug price controls continues to pick up speed in India, as pharmaceutical and biotech companies find their bottom lines impacted by unpredictable pricing policies and risk.
NEW DELHI – Indian biopharmaceutical companies are stepping up their forays into the biosimilars arena, with two firms announcing plans to expand their activities in the space over the past couple of weeks.
NEW DELHI – Indian biopharmaceutical companies are stepping up their forays into the biosimilars arena, with two firms announcing plans to expand their activities in the space over the past couple of weeks.
NEW DELHI – Claiming that the unregulated proliferation of online sales of pharmaceuticals in India could put lives at risk and threaten their businesses, some 800,000 pharmacies shut down for a day on Oct. 14. Online sales have been in the spotlight in recent months after the government sought out public input on how best to regulate the practice.
NEW DELHI – Claiming that the unregulated proliferation of online sales of pharmaceuticals in India could put lives at risk and threaten their businesses, some 800,000 pharmacies shut down for a day on Oct. 14.
NEW DELHI – Glenmark Pharmaceuticals SA, a Swiss subsidiary of Mumbai, India-based Glenmark Pharmaceuticals Ltd., completed phase I trials in the Netherlands of BBR 830, a monoclonal antibody (MAb) that targets a class of activated immune cells that are involved in several autoimmune disorders.
NEW DELHI – Glenmark Pharmaceuticals SA, a Swiss subsidiary of Mumbai, India-based Glenmark Pharmaceuticals Ltd., completed phase I trials in the Netherlands of BBR 830, a monoclonal antibody (MAb) that targets a class of activated immune cells that are involved in several autoimmune disorders.
